Illumina Debuts Two New Sequencers, Inks Dx Deal with Roche

The NextSeq 2000 and NextSeq 1000 are both designed to meet growing demand for clinical genomic data at reduced cost, while the collaboration with Roche is focused on advancing clinical diagnostics leveraging Illumina’s pan-cancer assay TruSight Oncology 500.
Illustration of a cancer cell

Researchers Discover New Gene Interaction Responsible for Cancer Metastasis

Investigators discovered that MYC and TWIST1, two transcription factors, together elicit a cytokinome whose signaling enabled crosstalk between cancer cells and host macrophages—driving tumor progression.
Fluidigm and Genomenon plan to create a joint panel design offering intended to help researchers accelerate the design of disease-specific next-generation sequencing

Element Biosciences Raises $80M to Accelerate Development of a New DNA Sequencing Platform

Led by ex-Illumina executives, Element’s founders believe its sequencing technology can reduce costs and inject more competition into a market dominated by their former employer.
Dendritic cell and T-lymphocytes, illustration

Johns Hopkins Researchers Refine TMB Calculations of Immunotherapy Response

The team developed a computational approach to estimate corrected TMB values for each tumor by simulating 20,000 tumors with various levels of TMB and sequencing coverage using information from the Cancer Genome Atlas to generate a correction factor for each simulated tumor based on its purity.
Fabric Genomics is partnering with data management company ITTM to provide secure genomic data hosting capabilities for European customers. (Source: iStock/© evryka23)

Large Scale Genomic Study Uncovers New Disease Targets

Children’s Hospital of Philadelphia researchers compared the sequence data of more than 100,000 people of European ancestry and found copy number variant (CNV) associations in four major disease categories: autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases.

Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with...

Biocept's Target Selector test enables physicians to identify the potential presence of NTRK fusions used to inform on treatment options.

Chromosome Alterations Contribute to Drug Resistance in ER+ Breast Cancer

Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.
pancreatic cancer cells

Genomic Analysis Reveals New Pancreatic Cancer Subtypes

The researchers identified five distinct subtypes of the disease: Basal-like-A, Basal-like-B, Classical-A, Classical-B, and Hybrid, each with unique molecular properties that could be targeted with novel chemotherapy treatments, biologics, and immunotherapies.

Small Sequencer Developer GenapSys Completes $90M Series C Financing

GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Color Genomics launched its $249 Color Test

Color to Collaborate with Sanford Health, Expand Northshore Partnership

Color will help Sanford move its Imagenetics genetic medicine program from an array-based platform to NGS testing, and will expand its partnership with NorthShore University HealthSystem—which has already enrolled 10K patients—to include 30 additional clinics.
Light micrograph of metastases in breast tissue

Triple Negative Breast Cancer Recurrence Prediction Method Developed

Women whose plasma contained circulating tumor DNA had only a 56% chance of being cancer-free two years following chemotherapy and surgery, while those without it had an 81% chance the cancer would not return in the same time span.
DNA research concept DNA barcodes for biomedical research  mitochondrial DNA  Prostate cancer DNA test

8 Companion Diagnostic Developers Making a Mark

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
ersonal Genome Diagnostics (PGDx) said today that its 500+ gene pan-cancer tumor profiling tissue assay is being used by Merck & Co. in a Phase II clinical trial designed to assess patient response to a dual biomarker-directed precision oncology combination therapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC).

Amgen Taps Guardant, Qiagen for AMG 510 NSCLC Companion Dx Partnerships

The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.
Nurse helping patient in hospital bed take a drink

Probiotic Drink Spiked with Genetic Elements Helps Thwart Antimicrobial Resistance

The drink targets small DNA elements called plasmids that carry antibiotic resistance genes. By preventing these plasmids from replicating, the antibiotic resistance genes are displaced, effectively re-sensitizing the bacteria to antibiotics.

LabCorp to Use New Thermo Fisher Genexus System for CDx, Oncology, Precision Medicine Applications

Once Genexus is validated, the automated platform could help accelerate access to next-generation sequencing (NGS) testing for clinical trials through LabCorp’s specialty and drug development central laboratories.
23andMe has raised an additional $250 million in growth financing

23andMe Inks Monoclonal Antibody Deal for Inflammatory Disease Therapeutic Development

The deal allows Spanish pharma Almirall to in-license 23andMe's bispecific monoclonal antibody designed to block all three members of the IL-36 cytokine subfamily, which is associated with multiple inflammatory diseases including various dermatological conditions.

GeneDx to Develop Clinical Assays Based on Bionano’s Saphyr System

GeneDx will develop assays targeting muscular dystrophies, developmental, and reproductive disorders using Saphyr, which detects CNVs, FSHD repeat contractions, repeat expansions, balanced and unbalanced translocations, and other complex rearrangements.
Biological specimen

New Security Concerns about DTC Genetic Testing Raised

In a UC Davis study, researchers described methods by which someone could learn database genotypes by uploading multiple datasets. For example, a person who uploads approximately 900 genomes could recover at least one allele at SNP sites across up to 82% of the genome of a median person of European ancestries.

Introduction to Cell Therapy

Sponsored content brought to you by Cell Therapy Overview CAR-T therapies have quickly shifted the direction of treatments for aggressive diseases, such as blood cancers,...
Genetic testing concept, DNA icon, medical doctor, isolated on white

ArcherDX’s Personalized Cancer Monitoring (PCM) Tech Gets FDA Breakthrough Device Designation

Breakthrough device designation is designed to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment, and review, while preserving FDA standards.
Freenome’s artificial intelligence (AI) genomics platform

Deep Learning Predicts Disease-Associated Mutations

For the first time, a deep-learning approach has been used to predict disease-associated metal-relevant site mutations in metalloproteins, providing a new platform to tackle human diseases.

Personal Genome Diagnostics to Develop LBx to Inform Eisai Drug Discovery Efforts

The two companies will look to develop a kitted NGS solution for the identification of biomarkers using blood samples collected from patients enrolled in clinical trials.
Diabetes mellitus metabolic disease signs and symptoms concept, 3D rendering

Actionable Type 2 Diabetes Risks Uncovered

More than 67 actionable clinical discoveries were made through deep longitudinal genomic analysis by a group led by Michael Snyder, MD, chair of the...
Source: Martin Barraud/Getty Images

10 Countries in 100K Genome Club

These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine

ArcherDx and Illumina to Partner, Co-Market In Vitro Diagnostics

The multi-year agreement covers co-marketing of future ArcherDX IVD tests used with the Illumina NextSeq 550Dx and MiSeq Dx Systems encompassing oncology testing—including companion diagnostics for therapeutic selection—personalized monitoring, and recurrence surveillance IVD tests.
Scroll Up